[1]
|
Villanueva, A. (2019) Hepatocellular Carcinoma. The New England Journal of Medicine, 380, 1450-1462.
https://doi.org/10.1056/NEJMra1713263
|
[2]
|
Feng, R., Zong, Y., Cao, S. and Xu, R.-H. (2019) Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Communications, 39, Article No. 22. https://doi.org/10.1186/s40880-019-0368-6
|
[3]
|
Sharma, S., Kowgier, M., Hansen, B., Brouwer, W.P., Maan, R., Wong, D., et al. (2018) Toronto HCC Risk Index: A Validated Scoring System to Predict 10-Year Risk of HCC in Patients with Cirrhosis. Journal of Hepatology, 68, 92-99.
https://doi.org/10.1016/j.jhep.2017.07.033
|
[4]
|
Nitiss, J.L. (2009) DNA Topoisomerase II and Its Growing Repertoire of Biological Functions. Nature Reviews Cancer, 9, 327-37. https://doi.org/10.1038/nrc2608
|
[5]
|
Wang, J.C. (2002) Cellular Roles of DNA Topoisomerases: A Molecular Perspective. Nature Reviews Molecular Cell Biology, 3, 430-440. https://doi.org/10.1038/nrm831
|
[6]
|
Erguden, H., Koksal, D., Demirag, F., Bayiz, H., Mutluay, N., Berktas, B., et al. (2012) The Association of Topoisomerase 2α Expression with Prognosis in Surgically Resected Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Disease, 4, 352-357.
|
[7]
|
Demoulin, B., Hermant, M., Castrogiovanni, C., Staudt, C. and Dumont, P. (2015) Resveratrol Induces DNA Damage in Colon Cancer Cells by Poisoning Topoisomerase II and Activates the ATM Kinase to Trigger p53-Dependent Apoptosis. Toxicology in Vitro, 29, 1156-1165. https://doi.org/10.1016/j.tiv.2015.04.015
|
[8]
|
Sudan, S. and Rupasinghe, H.P. (2014) Flavonoid-Enriched Apple Fraction AF4 Induces Cell Cycle Arrest, DNA Topoisomerase II Inhibition, and Apoptosis in Human Liver Cancer HepG2 Cells. Nutrition and Cancer, 66, 1237-1246.
https://doi.org/10.1080/01635581.2014.951733
|
[9]
|
Tang, Z., Li, C., Kang, B., Gao, G., Li, C. and Zhang, Z. (2017) GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Research, 45, W98-W102.
https://doi.org/10.1093/nar/gkx247
|
[10]
|
Yau, T., Hsu, C., Kim, T., Choo, S.P., Kang, Y.K., Hou, M.M., et al. (2019) Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. Journal of Hepatology, 71, 543-552.
https://doi.org/10.1016/j.jhep.2019.05.014
|
[11]
|
Agopian, V., Harlander-Locke, M., Markovic, D., Zarrinpar, A., Kaldas, F.M., Cheng, E.Y., et al. (2017) Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein. JAMA Surgery, 152, 55-64.
https://doi.org/10.1001/jamasurg.2016.3310
|
[12]
|
Luo, P., Wu, S., Yu, Y., Ming, X., Li, S., Zuo, X., et al. (2020) Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathology Oncology Research, 26, 599-603. https://doi.org/10.1007/s12253-019-00585-5
|
[13]
|
Tsochatzis, E., Meyer, T., O’Beirne, J., et al. (2013) Transarterial Chemoembolisation Is Not Superior to Embolisation Alone: The Recent European Association for the Study of the Liver (EASL)—European Organization for Research and Treatment of Cancer (EORTC) Guidelines. European Journal of Cancer, 49, 1509-1510.
https://doi.org/10.1016/j.ejca.2012.11.012
|
[14]
|
Kou, F., Sun, H., Wu, L., Li, B., Zhang, B., Wang, X., et al. (2020) TOP2A Promotes Lung Adenocarcinoma Cells’ Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma. Journal of Cancer, 11, 2496-508.
https://doi.org/10.7150/jca.41415
|
[15]
|
Dingemans, A.M., Witlox, M.A., Stallaert, R.A., van der Valk, P., Postmus, P.E. and Giaccone, G. (1999) Expression of DNA Topoisomerase IIalpha and Topoisomerase IIbeta Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer. Clinical Cancer Research, 5, 2048-2058.
|
[16]
|
Lazaris, A.C., Kavantzas, N.G., Zorzos, H.S., Tsavaris, N.V. and Davaris, P.S. (2002) Markers of Drug Resistance in Relapsing Colon Cancer. Journal of Cancer Research and Clinical Oncology, 128, 114-118.
https://doi.org/10.1007/s00432-001-0310-5
|
[17]
|
Zhang, R., Xu, J., Zhao, J. and Bai, J.H. (2018) Proliferation and Invasion of Colon Cancer Cells Are Suppressed by Knockdown of TOP2A. Journal of Cellular Biochemistry, 119, 7256-7263. https://doi.org/10.1002/jcb.26916
|
[18]
|
Zeng, S., Liu, A., Dai, L., Yu, X., Zhang, Z., Xiong, Q., et al. (2019) Prognostic Value of TOP2A in Bladder Urothelial Carcinoma and Potential Molecular Mechanisms. BMC Cancer, 19, Article No. 604.
https://doi.org/10.1186/s12885-019-5814-y
|
[19]
|
Nelson, W.G., Haffner, M.C. and Yegnasubramanian, S. (2018) The Structure of the Nucleus in Normal and Neoplastic Prostate Cells: Untangling the Role of Type 2 DNA Topoisomerases. American Journal of Clinical and Experimental Urology, 6, 107-113.
|
[20]
|
De Resende, M.F., Vieira, S., Chinen, L.T., Chiappelli, F., da Fonseca, F.P., Guimarães, G.C., et al. (2013) Prognostication of Prostate Cancer Based on TOP2A Protein and Gene Assessment: TOP2A in Prostate Cancer. Journal of Translational Medicine, 11, Article No. 36. https://doi.org/10.1186/1479-5876-11-36
|
[21]
|
Fritz, P., Cabrera, C.M., Dippon, J., Gerteis, A., Simon, W., Aulitzky, W.E., et al. (2005) c-erbB2 and Topoisomerase IIalpha Protein Expression Independently Predict Poor Survival in Primary Human Breast Cancer: A Retrospective Study. Breast Cancer Research, 7, Article No. R374. https://doi.org/10.1186/bcr1012
|
[22]
|
Badawy, O.M. and Loay, I. (2019) FISH Analysis of TOP2A and HER-2 Aberrations in Female Breast Carcinoma on Archived Material: Egyptian NCI Experience. Applied Immunohistochemistry & Molecular Morphology, 27, 216-222.
https://doi.org/10.1097/PAI.0000000000000574
|
[23]
|
Costa, M.J., Hansen, C.L., Holden, J.A. and Guinee, D. (2000) Topoisomerase II Alpha: Prognostic Predictor and Cell Cycle Marker in Surface Epithelial Neoplasms of the Ovary and Peritoneum. International Journal of Gynecological Pathology, 19, 248-257. https://doi.org/10.1097/00004347-200007000-00009
|
[24]
|
Panvichian, R., Tantiwetrueangdet, A., Angkathunyakul, N. and Leelaudomlipi, S. (2015) TOP2A Amplification and Overexpression in Hepatocellular Carcinoma Tissues. BioMed Research International, 2015, Article ID: 381602.
https://doi.org/10.1155/2015/381602
|
[25]
|
Ng, I., Na, J., Lai, E., Fan, S.T. and Ng, M. (1995) Ki-67 Antigen Expression in Hepatocellular Carcinoma Using Monoclonal Antibody MIB1. A Comparison with Proliferating Cell Nuclear Antigen. American Journal of Clinical Pathology, 104, 313-318. https://doi.org/10.1093/ajcp/104.3.313
|
[26]
|
Cai, H., Zhu, X., Qian, F., Shao, B., Zhou, Y., Zhang, Y., et al. (2020) High Expression of TOP2A Gene Predicted Poor Prognosis of Hepatocellular Carcinoma after Radical Hepatectomy. Translational Cancer Research, 9, 983-992.
https://doi.org/10.21037/tcr.2019.12.46
|
[27]
|
Anand, J., Sun, Y., Zhao, Y., Nitiss K.C. and Nitiss J.L. (2018) Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells. In: Drolet, M., Eds., DNA Topoisomerases, Vol. 1703, Humana Press, New York, 283-299.
https://doi.org/10.1007/978-1-4939-7459-7_20
|
[28]
|
Wong, N., Yen, W., Wong, W.-L., Wong, N.L.-Y., Chan, K.Y.-Y., Mo, F.K.-F., et al. (2009) TOP2A Overexpression in Hepatocellular Carcinoma Correlates with Early Age Onset, Shorter Patients Survival and Chemoresistance. International Journal of Cancer, 124, 644-652. https://doi.org/10.1002/ijc.23968
|